Gilead Sciences is investing $250m in LEO Pharma’s preclinical small molecules. According to the deal, Gilead will develop oral versions of the potential inflammation drugs, while Denmark’s LEO will focus on topical versions. Additional payments of up to $1.7bn could go to LEO, depending on the research’s progress. The molecules are being developed to target IL-4 and IL-13 proteins, known to be linked to inflammation.
Fake CAPTCHA Scam Targets Millions of University Students With Unknown Malware: Report
A fake CAPTCHA tricked millions of college students and professors into installing malware via education platform iClicker, which is used by 7 million students and
